nach oben

Indian Journal of Hematology and Blood Transfusion

Erschienen in:

01.09.2011 | Review Article

Hemophilia Care in India: A Review and Experience from a Tertiary Care Centre in Uttar Pradesh

verfasst von: Shubha Phadke

Erschienen in: Indian Journal of Hematology and Blood Transfusion | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Approximately 14,000 people with hemophilia are registered at the Hemophilia Federation of India; however, hemophilia remains under-diagnosed and many cases are not registered. In June 2009, the Government of Uttar Pradesh made anti-hemophilic factors available at a few centers, including the Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow. Consequently, the level of hemophilia care has improved considerably in recent times. Amongst the many challenges facing people with hemophilia, the development of inhibitors, which neutralize clotting factors provided by replacement therapy, is the most feared one. Healthcare professionals who treat people with hemophilia should not only be knowledgeable about the condition and committed to bettering the management of hemophilia, but also take responsibility for the judicious allocation of resources for various aspects of managing hemophilia. This manuscript aims to raise awareness regarding the detection and management of inhibitors in hemophilia based on the experience of a tertiary care hemophilia treatment centre in Uttar Pradesh, India.

Lee VN, Srivastava A, Nithyananth M, Kumar P, Cherian VM, Viswabandya A et al (2007) Fracture neck of femur in haemophilia A—experience from a cohort of 11 patients from a tertiary centre in India. Haemophilia 13:391–394PubMedCrossRef

Mammen J, Nair SC, Srivastava A (2007) External quality assessment scheme for hemostasis in India. Semin Thromb Hemost 33(3):265–272PubMedCrossRef

World Federation of Hemophilia (2009) Report on the annual global survey 2008. World Federation of Hemophilia, Montreal

Evatt BL, Black C, Batorova A, Street A, Srivastava A (2004) Comprehensive care for haemophilia around the world. Haemophilia 10(4):9–13PubMedCrossRef

Ghosh K, Shetty S, Sahu D (2010) Haemophilia care in India: innovations and integrations by various chapters of haemophilia federation of India (HFI). Haemophilia 16:61–65PubMedCrossRef

Ghosh K (2004) Management of haemophilia and its complications in developing countries. Clin Lab Haematol 26:243–251PubMedCrossRef

Kar R, Mirkazemi R, Singh P, Potnis-Lele M, Lohade S, Lalwani A et al (2007) Disability in Indian patients with haemophilia. Haemophilia 13:398–404PubMedCrossRef

Ananyeva NM, Lee TK, Jain N, Shima M, Saenko EL (2009) Inhibitors in hemophilia A: advances in elucidation of inhibitory mechanisms and in inhibitor management with bypassing agents. Semin Thromb Haemost 35(8):735–751CrossRef

Santagostino E, Morfini M, Auerswald GK-H, Benson GM, Šalek SZ, Lambert T et al (2009) Paediatric haemophilia with inhibitors: existing management options, treatment gaps and unmet needs. Haemophilia 15(5):983–989PubMedCrossRef

10.

Ören H, Yaprak I, İrken G (1999) Factor VIII inhibitors in patients with hemophilia a. Acta Haematol 102:42–46PubMedCrossRef

11.

McMillan CW, Shapiro SS, Whitehurst D, Hoyer LW, Rao AV, Lazerson J et al (1988) The Natural history of factor VIII: C inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII: C inhibitors. Blood 71(2):344–348PubMed

12.

Wang XF, Zhao YQ, Yang RC, Wu JS, Sun J, Zhang XS et al (2010) The prevalence of factor VIII inhibitors and genetic aspects of inhibitor development in Chinese patients with haemophilia A. Haemophilia 16(4):632–639PubMed

13.

Ghosh K, Shetty S, Kulkarni B, Nair S, Pawar A, Khare A et al (2001) Development of inhibitors in patients with haemophilia from India. Haemophilia 7(3):273–278PubMedCrossRef

14.

Mathews V, Nair SC, David S, Viswabandya A, Srivastava A (2009) Management of hemophilia in patients with inhibitors: the perspective from developing countries. Semin Thromb Haemost 35(8):820–826CrossRef

15.

Shetty S, Ghosh K, Pathare A, Pathare A, Mohanty D (2000) Clinically significant inhibitors in hemophilia A patients from India tend to persist. Acta Haematol 103(3):175–176PubMedCrossRef

16.

Ghosh K, Jijina F, Shetty S, Madkaikar M, Mohanty D (2002) First-time development of FVIII inhibitor in haemophilia patients during the postoperative period. Haemophilia 8(6):776–780PubMedCrossRef

17.

Wight J, Paisley S (2003) The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 9(4):418–435PubMedCrossRef

18.

Gouw SC, van den Berg HM (2009) The multifactorial etiology of inhibitor development in hemophilia: genetics and environment. Semin Thromb Haemost 35(8):723–734CrossRef

19.

Astermark J, Altisent C, Batorova A, Diniz MJ, Gringeri A, Holme PA et al (2010) Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report. Haemophilia 16(5):747–766PubMedCrossRef

20.

Ghosh K, Shetty S (2009) Immune response to FVIII in hemophilia A: an overview of risk factors. Clin Rev Allergy Immunol 37(2):58–66PubMedCrossRef

21.

Gouw SC, van der Bom JG, van den Berg HM (2007) Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 109(11):4648–4654PubMedCrossRef

22.

Sahud MA (2000) Laboratory diagnosis of inhibitors. Semin Thromb Haemost 26(2):195–203CrossRef

23.

Verbruggen B (2010) Diagnosis and quantification of factor VIII inhibitors. Haemophilia 16(102):20–24PubMedCrossRef

24.

Ewing NP, Kasper CK (1982) In vitro detection of mild inhibitors to factor VIII in hemophilia. Am J Clin Pathol 77(6):749–752PubMed

25.

Verbruggen B, van Heerd WL, Laros-van Gorkon BA (2009) Improvements in factor VIII inhibitor detection: from Bethesda to Nijmegen. Semin Thromb Haemost 35(8):752–759CrossRef

26.

van Geffen M, Dardikh M, Verbruggen B (2010) Factor VIII inhibitor assays: methodology, shortcomings, and challenges. J Coagulation Disord 2(1):15–21

27.

DiMichele DM, Hoots WK, Pipe SW, Rivard GE, Santagostino E (2007) International workshop on immune tolerance induction: consensus recommendations. Haemophilia 13(suppl 1):1–22PubMedCrossRef

28.

Astermark J, Rocino A, Von Depka M, van den Berg HM, Gringeri A, Mantovani LG et al (2007) Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors. Haemophilia 13(1):38–45PubMedCrossRef

29.

Astermark J, Donfield SM, DiMichele DM, Gringeri A, Gilbert SA, Waters J et al (2007) A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven comparative (FENOC) study. Blood 109(2):546–551PubMedCrossRef

30.

Baxter Healthcare Corporation (2005) FEIBA VH prescribing information. Baxter Healthcare Corporation, Westlake Village

31.

Negrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P (1997) Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA study group, factor eight bypassing activity. Thromb Haemost 77(6):1113–1119PubMed

32.

Kempton CL, White GC II (2009) How we treat hemophilia A patient with factor VIII inhibitor. Blood 113(1):11–17PubMedCrossRef

33.

Key NS, Aledort LM, Beardsley D, Cooper HA, Davignon G, Ewenstein BM et al (1998) Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 80(6):912–918PubMed

34.

Kavakli K, Makris M, Zulfikar B, Erhardtsen E, Abrams ZS, Kenet G et al (2006) Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. Thromb Haemost 95(4):600–605PubMed

35.

Young G, Shafer FE, Rojas P, Seremetis S (2008) Single 270 μg kg^-1-dose rFVIIa vs. standard 90 μg kg^-1-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia 14(2):287–294PubMedCrossRef

36.

Kavakli K, Yesilipek A, Antmen B, Aksu S, Balkan C, Yilmaz D et al (2010) The value of early treatment in patients with haemophilia and inhibitors. Haemophilia 16(3):487–494PubMed

37.

Giangrande PL, Wilde JT, Madan B, Ludlam CA, Tuddenham EG, Goddard NJ et al (2009) Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated); NovoSeven] in elective orthopaedic surgery in haemophilic patients with inhibitors. Haemophilia 15(2):501–508PubMedCrossRef

38.

Konkle BA, Ebbesen LS, Erhardtsen E, Bianco RP, Lissitchkov T, Rusen L et al (2007) Randomized, prospective clinical trial of rFVIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 5(9):1904–1913PubMedCrossRef

39.

Pandey GS, Phadke SR, Mittal B (2002) Carrier analysis and prenatal diagnosis of haemophilia A in North India. Int J Mol Med 10(5):661–664PubMed

40.

Pandey GS, Panigrahi I, Phadke SR, Mittal B (2003) Knowledge and attitudes towards haemophilia: the family side and role of haemophilia societies. Community Genet 6(2):120–122PubMedCrossRef

Titel: Hemophilia Care in India: A Review and Experience from a Tertiary Care Centre in Uttar Pradesh
verfasst von: Shubha Phadke
Publikationsdatum: 01.09.2011
Verlag: Springer-Verlag
Erschienen in: Indian Journal of Hematology and Blood Transfusion / Ausgabe 3/2011
Print ISSN: 0971-4502
Elektronische ISSN: 0974-0449
DOI: https://doi.org/10.1007/s12288-011-0084-0

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Hemophilia Care in India: A Review and Experience from a Tertiary Care Centre in Uttar Pradesh

Abstract

Neu im Fachgebiet Onkologie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2011

BK Virus Associated Late Onset Haemorrhagic Cystitis After Allogeneic Peripheral Blood Stem Cell Transplant

High Frequency of Inherited Variants in the MEFV Gene in Acute Lymphocytic Leukemia

Unusual Presentation of HIV Vasculopathy in a Child

Is it Primary Myelofibrosis or Chronic Lymphocytic Leukemia Related Secondary Myelofibrosis?

Expression of P-glycoprotein, Cyclin D1 and Ki-67 in Acute Lymphoblastic Leukemia: Relation with Induction Chemotherapy and Overall Survival

Factor XIII Deficiency in Siblings: Importance of Prophylactic Replacement

Neu im Fachgebiet Onkologie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

Update Onkologie